[{"address1": "Modi\u2019in Technology Park", "address2": "2 HaMa\u2019ayan Street", "city": "Hevel Modi'in", "zip": "7177871", "country": "Israel", "phone": "972 8 642 9100", "fax": "972 8 642 9101", "website": "https://www.biolinerx.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "BioLineRx Ltd., a commercial stage biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company's pipeline includes APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the treatment of pancreatic cancer, as well as completed Phase 3 clinical trial for the treatment of multiple myeloma. It also develops BL-5010, a pen-like applicator containing an acidic aqueous solution for the non-surgical removal of skin lesions. BioLineRx Ltd. was incorporated in 2003 and is headquartered in Hevel Modi'in, Israel.", "fullTimeEmployees": 79, "maxAge": 86400, "priceHint": 4, "previousClose": 0.59, "open": 0.6, "dayLow": 0.576, "dayHigh": 0.6049, "regularMarketPreviousClose": 0.59, "regularMarketOpen": 0.6, "regularMarketDayLow": 0.576, "regularMarketDayHigh": 0.6049, "beta": 0.926, "forwardPE": -1.4047619, "volume": 271799, "regularMarketVolume": 271799, "averageVolume": 445641, "averageVolume10days": 262050, "averageDailyVolume10Day": 262050, "bid": 0.5832, "ask": 0.6031, "bidSize": 200, "askSize": 200, "marketCap": 47164184, "fiftyTwoWeekLow": 0.55, "fiftyTwoWeekHigh": 2.53, "priceToSalesTrailing12Months": 4.046691, "fiftyDayAverage": 0.6608, "twoHundredDayAverage": 1.2484, "currency": "USD", "enterpriseValue": 624228608, "floatShares": 989893595, "sharesOutstanding": 79939296, "sharesShort": 219066, "sharesShortPriorMonth": 783550, "sharesShortPreviousMonthDate": 1713139200, "dateShortInterest": 1715731200, "sharesPercentSharesOut": 0.0027, "heldPercentInsiders": 0.08543, "heldPercentInstitutions": 0.01752, "shortRatio": 0.68, "impliedSharesOutstanding": 75170304, "bookValue": 0.012, "priceToBook": 49.166664, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1711843200, "netIncomeToCommon": -49148000, "trailingEps": -0.76, "forwardEps": -0.42, "pegRatio": 0.05, "lastSplitFactor": "1:15", "lastSplitDate": 1563148800, "enterpriseToRevenue": 53.559, "enterpriseToEbitda": -16.646, "52WeekChange": -0.6242038, "SandP52WeekChange": 0.26238096, "exchange": "NCM", "quoteType": "EQUITY", "symbol": "BLRX", "underlyingSymbol": "BLRX", "shortName": "BioLineRx Ltd.", "longName": "BioLineRx Ltd.", "firstTradeDateEpochUtc": 1311773400, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "e62a36f1-05bb-3c53-9aee-d33adfbdf394", "messageBoardId": "finmb_5015080", "gmtOffSetMilliseconds": -14400000, "currentPrice": 0.59, "targetHighPrice": 21.0, "targetLowPrice": 6.5, "targetMeanPrice": 13.75, "targetMedianPrice": 13.75, "recommendationMean": 2.0, "recommendationKey": "buy", "numberOfAnalystOpinions": 2, "totalCash": 28173000, "totalCashPerShare": 0.026, "ebitda": -37500000, "totalDebt": 11314000, "quickRatio": 1.319, "currentRatio": 1.494, "totalRevenue": 11655000, "debtToEquity": 86.631, "revenuePerShare": 0.18, "returnOnAssets": -0.40497002, "returnOnEquity": -1.884, "freeCashflow": -17292376, "operatingCashflow": -28701000, "grossMargins": 0.55839, "operatingMargins": -0.70343, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-06-24"}]